Cannabis and pharmacology
Browse the latest research linking medical marijuana / medicinal cannabis and pharmacology.
Cannabis and Cannabinoids Pharmacology
Click on a study title below to open a new tab with full article, or click on a compound to see it's full list of research.
in humans via placebo trial (n=15)
||Amygdala activity contributes to the dissociative effect of cannabis on pain perception.
Peripheral mechanisms alone cannot account for the dissociative effects of THC on the pain that was observed. Instead, the data reveal that amygdala activity contributes to interindividual response to cannabinoid analgesia, and suggest that dissociative effects of THC in the brain are relevant to pain relief in humans.
in humans via review
||A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
The half-life of cannabidiol was reported between 1.4 and 10.9 h after oromucosal spray, 2-5 days after chronic oral administration, 24 h after i.v., and 31 h after smoking. Bioavailability following smoking was 31% however no other studies attempted to report the absolute bioavailability of CBD following other routes in humans, despite i.v formulations being available. The area-under-the-curve and Cmax increase in dose-dependent manners and are reached quicker following smoking/inhalation compared to oral/oromucosal routes. Cmax is increased during fed states and in lipid formulations. Tmax is reached between 0 and 4 h.